20/20 Biolabs (AIDX) Financials: Revenue & Earnings
AIDX$0.24+0.01 +4.79%
$3.10M
Market Cap
—
P/E
—
Forward P/E
—
Score
20/20 Biolabs (AIDX) Financials: Revenue & Earnings
AIDX price $0.24 +0.01 +4.79%
- Ticker
- AIDX
- Price
- $0.24
- Change
- +0.01 +4.79%
- Market cap ?
- $3.10M
- Beta ?
- 1.54
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
Fair value
AIDX fair value $8.99. Price $0.24. Price is 97% below fair value.
Below fair value, and cheaper than usual. A larger discount than on 98% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Model uncertainty high for this stock
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-08-14 | -0.26 | -0.12 | 730.57K | 636.00K |
| 2026-05-20 | -0.28 | -0.10 | 353.38K | 779.00K |
| 2026-03-31 | -0.25 | — | 538.00K | — |
Dividends
Yield 0.00%. Payout ratio —. Frequency —.
Safety score 24/100 · At risk. Payout ratio is not reported, so this part stays neutral. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-02 | Bergman Alan B. | Buy | 100.00K | $1.88 | 188.00K |
| 2026-04-02 | Zhou Jiming | Buy | 150.00K | $1.88 | 282.00K |
| 2026-03-03 | Cohen Jonathan M | Buy | 352.94K | $3.39 | 1.20M |
| 2026-02-19 | Rollins John Woodson | Buy | 6.13K | — | — |
| 2026-02-19 | Rollins John Woodson | Buy | 13.03K | — | — |
| 2026-02-19 | Rollins John Woodson | Sell | 13.03K | — | — |
| 2026-02-19 | Rollins John Woodson | Sell | 6.13K | — | — |
| 2026-02-19 | Ross Michael A. | Buy | 31 | — | — |
| 2026-02-19 | Ross Michael A. | Sell | 31 | — | — |
| 2026-02-19 | Compton John G. | Buy | 7.67K | — | — |
| 2026-02-19 | Compton John G. | Sell | 7.67K | — | — |
| 2026-02-19 | COHEN RICHARD M | Buy | 7.70K | — | — |
| 2026-02-19 | COHEN RICHARD M | Sell | 7.70K | — | — |
| 2026-02-17 | Rollins John Woodson | Other | 0 | — | — |
| 2026-02-17 | Rollins John Woodson | Other | 13.03K | — | — |
| 2026-02-17 | Rollins John Woodson | Other | 6.13K | — | — |
| 2026-02-17 | Rollins John Woodson | Other | 30.00K | $1.74 | 52.20K |
| 2026-02-17 | Rollins John Woodson | Other | 30.00K | $2.55 | 76.50K |
| 2026-02-17 | Cohen Jonathan M | Other | 0 | — | — |
| 2026-02-17 | Cohen Jonathan M | Other | 388.00K | $1.74 | 675.12K |
| 2026-02-17 | Cohen Jonathan M | Other | 125.00K | $2.55 | 318.75K |
| 2026-02-17 | Lebowitz Michael Saul | Other | 50.00K | $1.74 | 87.00K |
| 2026-02-17 | Lebowitz Michael Saul | Other | 50.00K | $2.55 | 127.50K |
| 2026-02-17 | Baker Ron | Other | 50.00K | $1.74 | 87.00K |
| 2026-02-17 | Baker Ron | Other | 25.00K | $2.55 | 63.75K |
| 2026-02-17 | Bergman Alan B. | Other | 0 | — | — |
| 2026-02-17 | Reddy Prasanth | Other | 30.00K | $2.55 | 76.50K |
| 2026-02-17 | Compton John G. | Other | 0 | — | — |
| 2026-02-17 | Compton John G. | Other | 7.67K | — | — |
| 2026-02-17 | Compton John G. | Other | 30.00K | $1.74 | 52.20K |
| 2026-02-17 | Compton John G. | Other | 30.00K | $2.55 | 76.50K |
| 2026-02-17 | Zhou Jiming | Other | 352.00K | $1.74 | 612.48K |
| 2026-02-17 | COHEN RICHARD M | Other | 7.70K | — | — |
| 2026-02-17 | COHEN RICHARD M | Other | 30.00K | $1.74 | 52.20K |
| 2026-02-17 | COHEN RICHARD M | Other | 30.00K | $2.55 | 76.50K |
| 2026-02-17 | Ross Michael A. | Other | 31 | — | — |
| 2026-02-17 | Ross Michael A. | Other | 30.00K | $1.74 | 52.20K |
| 2026-02-17 | Ross Michael A. | Other | 30.00K | $2.55 | 76.50K |
| 2024-11-01 | Zhou Jiming | Other | 120.00K | $2.55 | 306.00K |
| 2022-02-01 | Rollins John Woodson | Other | 37.58K | $1.06 | 40.00K |
| 2022-02-01 | Compton John G. | Other | 37.58K | $1.06 | 40.00K |
| 2022-02-01 | COHEN RICHARD M | Other | 37.58K | $1.06 | 40.00K |
| 2022-02-01 | Ross Michael A. | Other | 37.58K | $1.06 | 40.00K |
| 2021-01-28 | Rollins John Woodson | Other | 76.63K | $1.04 | 80.00K |
| 2021-01-28 | Compton John G. | Other | 76.63K | $1.04 | 80.00K |
| 2021-01-28 | COHEN RICHARD M | Other | 76.63K | $1.04 | 80.00K |
| 2021-01-28 | Ross Michael A. | Other | 76.63K | $1.04 | 80.00K |
| 2019-08-01 | Rollins John Woodson | Other | 48.78K | $0.82 | 40.00K |
| 2019-08-01 | Compton John G. | Other | 48.78K | $0.82 | 40.00K |
| 2019-08-01 | COHEN RICHARD M | Other | 48.78K | $0.82 | 40.00K |
| 2019-08-01 | Ross Michael A. | Other | 48.78K | $0.82 | 40.00K |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 15, holders +8 vs prior quarter. Ownership 5.01%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| CRESSET ASSET MANAGEMENT, LLC | 240.12K | -24.25K | -9.17% | 132.00K |
| HRT FINANCIAL LP | 89.27K | 89.27K | New | 49.00K |
| VANGUARD FIDUCIARY TRUST CO | 52.09K | 52.09K | New | 28.65K |
| GEODE CAPITAL MANAGEMENT, LLC | 49.14K | 49.14K | New | 27.01K |
| ATLANTIC UNION BANKSHARES CORP | 35.10K | 35.10K | New | 19.29K |
| VANGUARD CAPITAL MANAGEMENT LLC | 24.53K | 24.53K | New | 13.49K |
| CITADEL ADVISORS LLC | 23.20K | 6.98K | +43.00% | 12.76K |
| BANK OF AMERICA CORP /DE/ | 13.02K | 13.02K | New | 7.15K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 10.01K | 10.01K | New | 5.50K |
| MCDONALD PARTNERS LLC | 2.80K | 2.80K | New | 1.54K |
| SIGNATUREFD, LLC | 767 | 767 | New | 422 |
| MORGAN STANLEY | 283 | 283 | New | 156 |
| ALLWORTH FINANCIAL LP | 172 | 142 | +473.33% | 95 |
| TOTH FINANCIAL ADVISORY CORP | 100 | -57 | -36.31% | 55 |
| UBS GROUP AG | 3 | -8.31K | -99.96% | 2 |
| MAI CAPITAL MANAGEMENT | 0 | -1.00K | -100.00% | 0 |
| XTX TOPCO LTD | 0 | -10.33K | -100.00% | 0 |
Earnings and financials
20/20 Biolabs Inc. (AIDX) trades at $0.24, with a market cap of $3.10M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Insights · Dividends · Forecast · Financials · Learn